Physician profile
Mohammad Shafi
NPI 1528052792
$2,815.49
in general payments reported to CMS, 2019-2025
28 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $168 · 2021: $194 · 2022: $23.30 · 2023: $433 · 2024: $667 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406 · Education: $82.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.86 |
| Education | $82.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $367.31 | 2019-2025 | |
| Amgen INC. | $341.26 | 2023-2025 | Krystexxa, Tavneos, Uplizna |
| Otsuka America Pharmaceutical, INC. | $335.86 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $306.97 | 2019-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $266.53 | 2019-2025 | Velphoro, Velphoro |
| Nxstage Medical, INC. | $153.09 | 2019-2024 | |
| Opko Pharmaceuticals, LLC | $141.31 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $119.95 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $108.11 | 2019-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $94.61 | 2019-2023 | Krystexxa |
| Daiichi Sankyo INC. | $59.56 | 2019-2020 | |
| Novo Nordisk INC | $58.84 | 2025 | Ozempic |
| Shire North American Group INC | $54.91 | 2019 | |
| Mallinckrodt Hospital Products INC. | $53.30 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $49.29 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $37.03 | 2024 | Intellis Adaptivestim |
| Calliditas Therapeutics US INC. | $33.61 | 2023 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $31.79 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $31.43 | 2019-2021 | |
| Ardelyx, INC. | $24.73 | 2024 | Ibsrela |
| Angiodynamics, INC. | $24.19 | 2019 | |
| Glaxosmithkline, LLC. | $22.73 | 2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $20.21 | 2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $19.89 | 2020 | |
| Covidien Lp | $15.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.30 | 2024 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.33 | 2024 | |
| Gilead Sciences, INC. | $13.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Shafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.